Combination targeted therapy for advanced EGFR-mutant lung cancer after first treatment fails
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two targeted drugs—sacituzumab tirumotecan (an antibody-drug conjugate) and furmonertinib (an EGFR inhibitor)—for people with EGFR-mutant lung cancer that has worsened after first-line treatment with a third-generation EGFR pill. The goal is to see if this combo can help control the cancer better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of lung cancer called non-squamous NSCLC that is advanced or has spread, and it is not suitable for surgery or radiation to cure it.
- Your cancer has a specific EGFR genetic change (like Ex19del or L858R) that makes it respond to EGFR-targeted drugs.
- Your cancer progressed (got worse) after your first treatment with a third-generation EGFR pill, but you have not started any new cancer treatment since.
- If you have brain metastases, they are stable (not growing, no new symptoms) and you do not need steroids or seizure medicine for at least 2 weeks.
- You are physically able to perform daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two newer drugs (sacituzumab tirumotecan and furmonertinib) together for patients with advanced non-squamous lung cancer whose tumors have specific genetic mutations and have stopped responding to earlier EGFR-targeted drugs and chemotherapy. The goal is to find out if this combination can help patients whose cancer has progressed.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
This study tests a combination of two targeted therapies for non-small cell lung cancer that has continued to grow despite previous EGFR-targeted treatment. It aims to see if adding gumarontinib (a MET inhibitor) to another EGFR-targeted drug can control the cancer for longer.
This trial tests whether a combination of two drugs, RC108 and Furmonertinib, can help people with non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutation and MET positivity) and cannot be removed by surgery. It is for people who have not yet received treatment for their advanced or metastatic cancer.
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.